Ranchi News Desk

COVID-19 (CoronaVirus) Clinical Trial Insight, Pipeline Assessment, Emerging Drugs | DelveInsight

 Breaking News
  • No posts were found

COVID-19 (CoronaVirus) Clinical Trial Insight, Pipeline Assessment, Emerging Drugs | DelveInsight

April 14
05:10 2020
COVID-19 (CoronaVirus) Clinical Trial Insight, Pipeline Assessment, Emerging Drugs | DelveInsight

COVID-19 (CoronaVirus) – Pipeline Insight, 2020

 

DelveInsight has launched a new report on “COVID-19(CoronaVirus) – Pipeline Insight, 2020

 

“COVID-19(CoronaVirus) – Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across COVID-19 (CoronaVirus). A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type.

 

Products covered by Phase

  • Phase III, Phase II, Phase I
  • Pre-clinical & Discovery
  • Inactive (Discontinued and Dormant)

 

Overview of pipeline development activities for COVID-19(CoronaVirus)

Pipeline analysis of therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and pre-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.

 

Request For a Sample Report or Webex Demo: https://www.delveinsight.com/report-store/covid-19-coronavirus-pipeline-insights?utm_source=ABNewswire&utm_medium=Ankit-PressRelease&utm_campaign=Covid%2019%20Pipeline%20Insight%202020

 

Therapeutic segmentation of products for COVID-19(CoronaVirus)

The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this indication.

 

Methodology

Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.

Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

 

Request For Sample Pages: https://www.delveinsight.com/sample-request/covid-19-coronavirus-pipeline-insights?utm_source=ABNewswire&utm_medium=Ankit-PressRelease&utm_campaign=Covid%2019%20Pipeline%20Insight%202020

 

Scope of the report

• Provides an overview of therapeutic pipeline activity for COVID-19(CoronaVirus) across the complete product development cycle including all clinical and non-clinical stages

• It comprises of detailed profiles of COVID-19(CoronaVirus) therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, designations, technologies and chemical information

• Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration

• Coverage of dormant and discontinued pipeline projects across COVID-19(CoronaVirus)

 

Reasons to Buy

• Establish a comprehensive understanding of the current pipeline scenario across COVID-19(CoronaVirus) to formulate effective R&D strategies

• Assess challenges and opportunities that influence COVID-19(CoronaVirus) R&D

• Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage

• Identify the relationship between the product and use it for target finding, drug repurposing, and precision medicine

• Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for COVID-19(CoronaVirus) to enhance and expand business potential and scope

• Our extensive domain knowledge on therapy areas support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs

 

Request For Sample Pages: https://www.delveinsight.com/sample-request/covid-19-coronavirus-pipeline-insights?utm_source=ABNewswire&utm_medium=Ankit-PressRelease&utm_campaign=Covid%2019%20Pipeline%20Insight%202020

 

Table Of Contents:

1. Report Introduction

2. COVID-19(CoronaVirus) – Disease Overview

3. Pipeline Outlook

   • An Overview of Pipeline Products for COVID-19(CoronaVirus)

4. Comparative Analysis

5. COVID-19(CoronaVirus) Therapeutic Products in Clinical Stage

   5.1 Drug Name : Company Name

         • Product Description

         • Research and Development

         • Product Development Activities

Other product profiles in the detailed report…..

6. COVID-19(CoronaVirus) Therapeutic Products in Non-clinical Stage

    6.1 Drug Name : Company Name

           • Product Description

           • Research and Development

           • Product Development Activities

Other product profiles in the detailed report…..

7. Therapeutic Pipeline Analysis

   • Pipeline Analysis by Route of Administration

   • Pipeline Analysis by Stage and Route of Administration

   • Pipeline Analysis by Molecule Type

   • Pipeline Analysis by Stage and Molecule Type

8. Inactive Pipeline Products

   8.1 Drug Description

         • Research and Development Studies

         • Product Development Activities

         • Reason for dormancy/discontinuation

9. Appendix

10. Report Methodology

11. Consulting Services

12. Disclaimer

13. About DelveInsight

 

Request For Sample Pages: https://www.delveinsight.com/sample-request/covid-19-coronavirus-pipeline-insights?utm_source=ABNewswire&utm_medium=Ankit-PressRelease&utm_campaign=Covid%2019%20Pipeline%20Insight%202020

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/